GBA1 Gene Correction Before Stem Cell Differentiation for DA Neurons
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for differentiating pluripotent stem cells into lineage-specific cell populations for treating neurodegenerative diseases like Parkinson's Disease are limited in producing physiologically consistent cells and often involve cells with gene variants associated with an increased risk of PD, hindering effective engraftment and innervation.
Innovation Solution
A method involving the use of recombinant nucleases and single-stranded DNA oligonucleotides (ssODNs) for homology-directed repair (HDR) to correct gene variants in pluripotent stem cells, specifically targeting the GBA1 gene, to integrate a corrected form of the SNP, thereby producing physiologically consistent cells for cell replacement therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pluripotent stem cells are differentiated into lineage-specific cell populations for treating neurodegenerative diseases, then cell replacement therapy can be provided, but the cells may retain gene variants associated with increased risk of Parkinson's Disease and show limited ability to engraft and innervate
Solution Approach 1:
The patent extracts and removes the harmful gene variant (SNP) from the stem cells using CRISPR-Cas9 gene editing technology. By targeting the specific problematic sequence in the GBA1 gene and replacing it with a corrected version, the harmful genetic factor is separated from the beneficial cellular function, allowing cells to be used for therapy without the associated disease risk.
Solution Approach 2:
The patent performs gene correction as a preliminary action before differentiating stem cells into therapeutic cell populations. By correcting the GBA1 gene variant in the pluripotent stem cells prior to differentiation, the cells are pre-conditioned to lack the harmful genetic factor, ensuring that subsequent differentiation into dopaminergic neurons or other lineage-specific cells produces therapeutically effective cells without disease risk.
2Object-affected harmful factors
If gene editing is performed to correct GBA1 variants, then cells with reduced PD risk can be produced, but the process complexity increases
Solution Approach 1:
The patent uses ssODN (single-stranded oligodeoxynucleotide) as an intermediary molecule to facilitate precise gene correction. The ssODN serves as a template that mediates the replacement of the mutant GBA1 sequence with the correct sequence through homology-directed repair, simplifying the editing process compared to traditional methods while maintaining high precision.
Solution Approach 2:
The patent changes the molecular parameters of the DNA repair process by utilizing homology-directed repair with ssODN templates. This approach modifies the repair mechanism parameters to favor precise correction over error-prone repair pathways, achieving high-fidelity gene correction with controlled efficiency.
3Productivity
If cells are differentiated without gene correction, then the process is simpler and faster, but the cells lack physiological consistency and engraftment ability
Solution Approach 1:
The patent performs gene correction in the pluripotent stem cell stage before differentiation, which is the most efficient time to edit the genome. This preliminary action ensures that all subsequent differentiated cells inherit the corrected genotype, achieving physiological consistency across the entire cell population without slowing down the differentiation process.
Solution Approach 2:
The patent segments the therapeutic cell production process into two distinct phases: (1) gene correction in pluripotent stem cells, and (2) differentiation into lineage-specific cells. This segmentation allows each phase to be optimized independently, maintaining high differentiation efficiency while ensuring genetic precision in the final therapeutic product.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively corrects gene variants associated with Parkinson's Disease, producing cells that are more likely to engraft and innervate, enhancing the efficacy of cell replacement therapies for neurodegenerative conditions.
Implementation Method 1
introducing, into a cell, one or more agents comprising a recombinant nuclease for inducing a DNA break within an endogenous target gene in the cell
Implementation Method 2
the introducing of the one or more agents and the ssODN results in homology-directed repair (HDR) and integration of the ssODN into the target gene
Data Source
AI summary
The present disclosure provides methods of correcting gene variants associated with Parkinson's Disease in pluripotent stem cells, and methods of lineage specific differentiation of such corrected pluripotent stem cells into floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and/or DA neurons, or into glial cells, such as microglial cells, astrocytes, oligodendrocytes, or ependymocytes. Also provided are compositions uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease.